Time to Reconsider Neogenomics Incorporated (NASDAQ:NEO) After More Short Sellers?

July 18, 2017 - By Michael Collier

 Time to Reconsider Neogenomics Incorporated (NASDAQ:NEO) After More Short Sellers?

Investors sentiment decreased to 1.15 in Q4 2016. Its down 0.10, from 1.25 in 2016Q3. It dived, as 11 investors sold NeoGenomics, Inc. shares while 44 reduced holdings. 19 funds opened positions while 44 raised stakes. 58.46 million shares or 2.70% more from 56.93 million shares in 2016Q3 were reported.
California State Teachers Retirement Sys holds 109,330 shares. Prudential Fin Inc reported 22,079 shares stake. Axiom International Investors Limited Liability De, a Connecticut-based fund reported 285,725 shares. Northwestern Mutual Wealth Mgmt Communications reported 0% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO). First United Bankshares reported 44,000 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 3,530 shares. Allianz Asset Ag holds 800,588 shares or 0.01% of its portfolio. Ruggie has invested 0.03% in NeoGenomics, Inc. (NASDAQ:NEO). Meristem Llp invested 0.04% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO). Alliancebernstein Limited Partnership holds 33,800 shares or 0% of its portfolio. 288,923 are owned by Bard Associate. Granite Inv Prns Lc holds 1.23M shares or 0.78% of its portfolio. Swiss Commercial Bank invested in 121,700 shares or 0% of the stock. Teton reported 0.16% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO). Wells Fargo Mn holds 0% of its portfolio in NeoGenomics, Inc. (NASDAQ:NEO) for 203,154 shares.

Since March 13, 2017, it had 0 insider buys, and 4 selling transactions for $1.10 million activity. 50,000 shares valued at $396,655 were sold by BRODIE STEVEN G. on Monday, March 13. BALLIET JENNIFER also sold $25,005 worth of NeoGenomics, Inc. (NASDAQ:NEO) shares. ROSS STEVEN A sold $549,389 worth of stock or 70,833 shares.

The stock of Neogenomics Incorporated (NASDAQ:NEO) registered an increase of 1.18% in short interest. NEO’s total short interest was 6.88M shares in July as published by FINRA. Its up 1.18% from 6.80 million shares, reported previously. With 379,200 shares average volume, it will take short sellers 18 days to cover their NEO’s short positions. The short interest to Neogenomics Incorporated’s float is 12.81%.

The stock increased 0.33% or $0.03 during the last trading session, reaching $9.24. About shares traded. NeoGenomics, Inc. (NASDAQ:NEO) has declined 13.46% since July 18, 2016 and is downtrending. It has underperformed by 30.16% the S&P500.

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The company has market cap of $736.95 million. The Firm operates in Laboratory Testing Segment. It currently has negative earnings. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers.

NeoGenomics, Inc. (NASDAQ:NEO) Ratings Coverage

Among 9 analysts covering NeoGenomics (NASDAQ:NEO), 8 have Buy rating, 1 Sell and 0 Hold. Therefore 89% are positive. NeoGenomics has $11 highest and $8 lowest target. $10.07’s average target is 8.98% above currents $9.24 stock price. NeoGenomics had 14 analyst reports since September 3, 2015 according to SRatingsIntel. TH Capital reinitiated the stock with “Buy” rating in Monday, October 26 report. The stock has “Neutral” rating by BTIG Research on Wednesday, July 27. The rating was maintained by William Blair with “Outperform” on Sunday, September 6. Benchmark initiated the stock with “Buy” rating in Friday, March 11 report. The rating was maintained by Roth Capital with “Buy” on Friday, May 26. The firm earned “Buy” rating on Friday, May 26 by BTIG Research. The stock of NeoGenomics, Inc. (NASDAQ:NEO) earned “Overweight” rating by First Analysis on Tuesday, October 4. Roth Capital reinitiated the stock with “Buy” rating in Wednesday, May 11 report. Cantor Fitzgerald maintained NeoGenomics, Inc. (NASDAQ:NEO) on Friday, May 26 with “Buy” rating. Roth Capital maintained the shares of NEO in report on Thursday, September 3 with “Buy” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: